Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02392364 · ClinicalTrials.gov registry record · Phase 4
Variable Interval Versus Set Interval Aflibercept for DME
A Phase 4 study, sponsored by California Retina Consultants.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT02392364 is a Phase 4 study that has completed, run by California Retina Consultants. The registered enrollment target is 50 participants.
The verdict
NCT02392364, a Phase 4 study, has completed, sponsored by California Retina Consultants.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of intravitreal Eylea injections at a set interval, versus a variable dosing schedule (likely longer than one month), based on a specific individual's disease progression. There will be approximately 50 men and women at least 18 years of age, diagnosed with type 1 or type 2 diabetes, taking part in this study at 5 locations in the United States.
Interventions
- DRUG Intravitreal Aflibercept Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-04-15 |
| Est. Completion | 2018-11-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02392364
The ClinicalTrials.gov registry entry for NCT02392364 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is California Retina Consultants, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravitreal Aflibercept Injection is the first listed.
NCT02392364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02392364 about?
NCT02392364 is a clinical study titled "Variable Interval Versus Set Interval Aflibercept for DME". The purpose of this study is to compare the safety and efficacy of intravitreal Eylea injections at a set interval, versus a variable dosing schedule (likely longer than one month), based on a specific individual's disease progression. There will be approximately 50 men and women at least 18 years o...
What is the current status of trial NCT02392364?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2015-04-15. Estimated completion is 2018-11-15.
What interventions are being tested in trial NCT02392364?
The interventions under investigation include: Intravitreal Aflibercept Injection (DRUG).
Who is sponsoring clinical trial NCT02392364?
This trial is sponsored by California Retina Consultants, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.